Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR27 | Q9NS67 | 1/20 | 0.46 |
| ▸ | JAK3 | P52333 | 1/20 | 0.45 |
| ▸ | BTK | Q06187 | 1/20 | 0.45 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.43 |
| ▸ | CA12 | O43570 | 1/20 | 0.42 |
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | CA9 | Q16790 | 1/20 | 0.42 |
| ▸ | NTRK1 | P04629 | 3/20 | 0.41 |
| ▸ | SMO | Q99835 | 1/20 | 0.41 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.41 |
| ▸ | SORT1 | Q99523 | 2/20 | 0.41 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.40 |
| ▸ | NTRK2 | Q16620 | 1/20 | 0.40 |
| ▸ | AURKA | O14965 | 2/20 | 0.40 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2311432 | 0.92 | BTK (0.45) | JAK3BTKCA12CA1CA2 | |
| SCHEMBL2311479 | 0.90 | JAK3 (0.49) | GPR27JAK3BTKTRPV4CA12 | |
| SCHEMBL2314903 | 0.88 | JAK3 (0.49) | JAK3BTKCA12CA1CA2 | |
| SCHEMBL2310942 | 0.87 | ALDH1A1 (0.49) | GPR27JAK3BTKCA12CA1 | |
| SCHEMBL2313734 | 0.87 | JAK2 (0.52) | JAK3BTKCA12CA1CA2 | |
| SCHEMBL15937424 | 0.86 | PLG (0.42) | JAK3BTKPTGDR2GAASMN1; SMN2 | |
| SCHEMBL2312595 | 0.86 | PTGS1 (0.52) | JAK3BTKTRPV4CA12CA1 | |
| SCHEMBL2312265 | 0.85 | BACE1 (0.51) | GPR27JAK3BTKPTGDR2GAA | |
| SCHEMBL2307990 | 0.84 | MEN1 (0.52) | SMN1; SMN2 | |
| Acoziborole SCHEMBL1164186 | 0.83 | JAK3 (0.49) | JAK3BTKCA12CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190256530-A1 | BORON-CONTAINING SMALL MOLECULES AS ANTIPROTOZOAL AGENTS | ANACOR PHARMACEUTICALS, INC. | 2019-08-22 | — | — | US | disclosed |
| US-20190256530-A1 | BORON-CONTAINING SMALL MOLECULES AS ANTIPROTOZOAL AGENTS | ANACOR PHARMACEUTICALS, INC. | 2019-08-22 | — | — | US | disclosed |
| US-10301329-B2 | Boron-containing small molecules as antiprotozoal agents | ANACOR PHARMACEUTICALS, INC. (US) | 2019-05-28 | — | — | US | disclosed |
| US-10301329-B2 | Boron-containing small molecules as antiprotozoal agents | ANACOR PHARMACEUTICALS, INC. (US) | 2019-05-28 | — | — | US | disclosed |
| US-20160340369-A1 | BORON-CONTAINING SMALL MOLECULES AS ANTIPROTOZOAL AGENTS | ANACOR PHARMACEUTICALS, LLC | 2016-11-24 | — | — | US | disclosed |
| US-20160340369-A1 | BORON-CONTAINING SMALL MOLECULES AS ANTIPROTOZOAL AGENTS | ANACOR PHARMACEUTICALS, LLC | 2016-11-24 | — | — | US | disclosed |
| US-9440994-B2 | Boron containing small molecules as antiprotozoal agents | ANACOR PHARMACEUTICALS, INC. (US) | 2016-09-13 | — | — | US | disclosed |
| US-9440994-B2 | Boron containing small molecules as antiprotozoal agents | ANACOR PHARMACEUTICALS, INC. (US) | 2016-09-13 | — | — | US | disclosed |
| US-20110190235-A1 | BORON-CONTAINING SMALL MOLECULES AS ANTIPROTOZOAL AGENTS | ANACOR PHARMACEUTICALS, INC. (US) | 2011-08-04 | — | — | US | disclosed |
| US-20110190235-A1 | BORON-CONTAINING SMALL MOLECULES AS ANTIPROTOZOAL AGENTS | ANACOR PHARMACEUTICALS, INC. (US) | 2011-08-04 | — | — | US | disclosed |
| WO-2011019618-A1 | BORON-CONTAINING SMALL MOLECULES AS ANTIPROTOZOAL AGENTS | ANACOR PHARMACEUTICALS, INC. (US) | 2011-02-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110190235-A1 | BORON-CONTAINING SMALL MOLECULES AS ANTIPROTOZOAL AGENTS | BTD, BAD, BRI3BP | GPR27 3262/4885JAK3 3665/4885BTK 68/4885 |
| US-20160340369-A1 | BORON-CONTAINING SMALL MOLECULES AS ANTIPROTOZOAL AGENTS | BTD, BAD, BRI3BP | GPR27 3262/4885JAK3 3665/4885BTK 68/4885 |
| US-10301329-B2 | Boron-containing small molecules as antiprotozoal agents | BTD, BAD, BRI3BP | GPR27 3262/4885JAK3 3665/4885BTK 68/4885 |
| US-20190256530-A1 | BORON-CONTAINING SMALL MOLECULES AS ANTIPROTOZOAL AGENTS | BTD, BAD, BRI3BP | GPR27 3262/4885JAK3 3665/4885BTK 68/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.